of the main causes of AIDS-associated death in these subjects [3, 4] . Moreover, the incidence of Hodgkin lymphoma has increased during the HAART era [5] .
In the general population, high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) are the treatments of choice for relapse of nonHodgkin lymphoma and Hodgkin lymphoma [6, 7] . Our research group and others have shown that ASCT is also feasible and effective in HIV-infected persons [8] [9] [10] [11] [12] [13] [14] .
HIV infection causes a severe depletion of CD4 + T lymphocytes, which leads to a reduction in the heterogeneity of T cell receptor expression, a decrease in the phenotypically defined naive CD4 + T cell count, and a decrease in thymic regeneration, which is measured as circular fragments of episomal DNA of the T cell receptor (signal joint T cell receptor rearrangement excision circles [sjTRECs]) [15] [16] [17] [18] . Undoubtedly, HDC could exacerbate immunodepression that already affects HIV-infected patients and consequently facilitate the progression of infection. However, as with HIV-uninfected patients, conditioning regimens could also create an appropriate lymphoid space that is devoid of endogenous cellular populations competing for stimulatory cytokines; this may advantage expansion of the transferred cells [19, 20] . Nevertheless, the dynamics of immune reconstitution, thymic regeneration, and viral replication have to be studied to optimize therapeutic strategies that target HIVrelated lymphoma and HIV infection.
The aims of this study are (1) to compare the pretreatment immune status of HIV-infected and HIV-uninfected individuals with relapsed or refractory lymphoma who underwent comparable ASCT protocols, to assess whether conventional chemotherapy has a different impact on the immune system of the 2 populations; (2) to describe the dynamics of immune reconstitution and thymic regeneration at up to 24 months of follow-up; and (3) to explain the dynamics of HIV replication during treatment and after ASCT.
MATERIALS AND METHODS

Patients.
From October 2001 to March 2008, all HIV-infected patients (n p 24; 18 had high-grade non-Hodgkin lymphoma, and 6 had Hodgkin lymphoma) and HIV-uninfected patients (n p 9; all had high-grade non-Hodgkin lymphoma) with lymphoma that had relapsed or that was refractory to first-line chemotherapy, who received comparable HDC and ASCT protocols and showing at least 1-month follow-up after transplantation, were included in a prospective, immunovirologic study. The DCT for patients with high-grade non-Hodgkin lymphoma treated up to November 2002 consisted of 4 cycles of etoposide, cytarabine, cisplatinum, and methylprednisone; the regimen of dexamethasone, high-dose cytarabine and oxaliplatinum was used for patients treated thereafter. Before each cycle, rituximab was administered to all patients who had CD20 + high-grade non-Hodgkin lymphoma. For HIV-infected patients with relapsed Hodgkin lymphoma, the DCT consisted of 4 cycles of mesna, iphosphamide, mitoxantrone, etoposide, and prednisolone. The mobilization of CD34 + cells and the conditioning regimen were previously described elsewhere [21, 22] + collection (aphaeresis), before HDC, 15 days after reinfusion (aplasia), and 1, 3, 6, 12, and 24 months after ASCT. sjTRECs were not assessed at aphaeresis, 15 days after reinfusion, and at month 1 and 6 of follow-up; HIV DNA levels were also not determined at month 6.
All patients were monitored for the development of infectious complications. An infectious episode was assigned if there was clinically or microbiologically documented infection and/ or fever without a localized source of infection or identified pathogen. Grading of the infections was scored according to Common Toxicity Criteria [23] . Antibacterial, antifungal, and (on the basis of individual history) antiviral prophylaxis were administered to all patients from the start of conditioning until neutrophil recovery. At enrollment, all HIV-infected patients were receiving HAART based on their clinical antiretroviral therapy histories and/or the HIV genotypic test result.
All patients agreed to participate in the study by signing an informed consent approved by our Institute Board of Ethics, in agreement with principles stated in the Declaration of Helsinki.
Immunovirologic characterization. The absolute lymphocyte subset counts were evaluated by a single platform, wholeblood lysing technique and with the EPICS XL flow cytometer (Beckman-Coulter), as described elsewhere [18] . Nave CD4 + T cells were defined by 3-color flow cytometry using monoclonal antibodies against CD4 (Dako), CD62L (Immunotech), and CD45RA (Beckman-Coulter) antigens [24] .
Thymic regeneration was evaluated by assessing the number of sjTRECs per 10 6 peripheral blood mononuclear cells (PBMCs) using a real-time polymerase chain reaction (PCR) quantitative technique [18] . The HIV RNA level was quantified by using the Versant HIV-1 RNA 3.0 assay kit (b-DNA; Bayer Diagnostics). The HIV DNA level was measured by real-time PCR [22] .
Statistical analysis. Significant tests for proportions were computed using the Fisher exact test. We used the Mann Whitney U test to evaluate the differences between groups in continuous variables (HIV-infected vs HIV-uninfected patients, HIV-infected patients with infectious episodes vs HIV-infected patients without infectious episodes, and rituximab-treated vs rituximab-untreated patients) and the Wilcoxon rank sum test for longitudinal analysis of matched data. Correlations between the immunological covariates at baseline and 3 and 12 months after ASCT were analyzed using the Spearman coefficient. Except for CD56 + cells, the concentration of lymphocyte subsets in the aphaeretic product correlated well with that found in peripheral blood at aphaeresis (12 observations; r p 0.77-0.90; P ! .005). Considering these results, to increase the power of statistical analyses, we evaluated the associations between the peripheral T cell subsets at aphaeresis and the subset recoveries at 3 and 12 months after ASCT. For CD56 + recovery, we used CD56 + concentrations found in the aphaeretic product. Moreover, CD34 + cells were considered as covariates. At all time points, some data were missing because of sampling and/or technical gaps. Analyses were performed with SAS software, version 8.2 (SAS Institute). Results were considered statistically significant at a 2-tailed P value р.05.
RESULTS
Baseline characteristics.
No differences were observed in demographic and clinical characteristics before DCT between HIV-infected and HIV-uninfected patients, except for age (Table 1). evident at aphaeresis and, except for immediately after transplantation, until 24 months after ASCT (P p .001-.04) ( Figure  1A) . However, the kinetics of CD4 + T cell counts demonstrated a similar trend in both groups. In fact, after challenge with granulocyte colony-stimulating factor, CD4
+ T lymphocyte counts increased in both groups, although the increase was 
CD4
+ T cell levels were achieved after 6 and 3 months following ASCT in HIV-infected and HIV-uninfected patients, respectively. It is worth noting that CD4 + T cell counts evidenced a temporary setback at 3 months in HIV-infected patients, followed by a steady enhancement, reaching 32% and 58% increases versus baseline at 12 and 24 months after ASCT, respectively. Otherwise, HIVuninfected patients experienced a steady increase, reaching a 47% increment over the baseline value at 24 months after ASCT. With regard to naive CD4 + T lymphocytes, both HIV-infected and HIV-uninfected patients attained the initial median values 12 months after ASCT ( Figure 1B) .
After aplasia, the CD8 + T lymphocytes underwent a rapid expansion in both populations. They exceeded baseline values 1 month after ASCT and remained persistently high during the entire follow-up period ( Figure 1C) . It is worth noting that this increase led to a reversal in the ratio of CD4 + cells to CD8 , which remained reverted even 2 years after ASCT ( Figure 1D ). As with the CD8 + T lymphocytes, CD56 + NK lymphocyte counts recovered rapidly both in HIV-infected patients and in HIV-uninfected patients, slightly overcoming baseline values р1 month after ASCT and not changing substantially during the 24 months after ASCT ( Figure 1E) .
In both populations, the CD19 + cells were virtually absent in the aplastic period; the CD19 + cell count had recovered somewhat by 3 months after transplantation, and median values reached the normal range [25] by 6 months after transplantation ( Figure 1F ). Subsequently, a marked enhancement in absolute numbers was observed until year 2 after transplan- 6 PBMCs]; P p .04) (Figure 2) . By month 24, sjTREC values had increased additionally in both groups.
Determinants of immunological recovery. We investigated whether the recovery of immunological parameters up to 12 months from ASCT could be associated with the concentration of cell subtypes at baseline and at the time of aphaeresis and/ or with the amount of reinfused CD34 + stem cells. We found that naive CD4 + T cell counts at baseline were correlated with recovery of the same T cell subset at month 3 after ASCT (r The subset concentration at the time of aphaeresis influenced the corresponding recovery of all T cell subsets at 3 months after ASCT (r p0.55-0.61; P p .002-.02). This influence was slightly less evident for CD4 + and CD8 + T subsets at month 12 after ASCT, with the correlation model assessment being less fit (r p0.48-0.55; P р .05). On the contrary, CD34
+ cells correlated well with the recovery in B cells (r p 0.50, P ! .05), NK cells (r p 0.46, P ! .05), and sjTRECs (r p 0.45, P p .05) at month 12 after ASCT.
Dynamics of viral replication. At enrollment, 16 patients had undetectable viral loads, 4 had viral loads of 204-1272 copies/mL, 1 had a viral load of 36,896 copies/mL, 1 had a viral load of 305,426 copies/mL, and 2 had missing data. Before transplantation, 23 of 24 patients had HIV RNA levels that were less than the detection limit. The 1 patient with detectable viremia had a multidrug-resistant HIV-1 genotype. Ten patients discontinued HAART during HDC because of hepatic and/or gastroenteric toxicity. Among these patients, 8 had a viral load rebound during the aplastic period and 1 had a viral load rebound 1 month from ASCT. However, after HAART reintroduction, 7 patients showed a virological response in 4 weeks (reduction in the HIV RNA level, 0.5-3 log 10 copies/mL). Only 2 of 14 patients, who were consistently receiving HAART, presented with sporadic viral load "blips," which did not exceed 200 copies/mL (1 month after transplantation in one subject and 12 months after transplantation in the other).
At the time of enrolment, HIV DNA levels were very low (median, 75 copies/10 6 PBMCs; IQR, 41-165 copies/10 6 PBMCs). Slight, transient, and nonsignificant fluctuations were observed until month 12 after transplantation, whereas HIV DNA values at month 24 after transplantation were significantly lower than those at baseline (median, 8 copies/10 6 PBMCs; IQR, 5-58 copies/ 10 6 PBMCs; P p .04) (Figure 3 ). Infectious complications after ASCT. Infectious complications during the first 3 months after ASCT were rare among HIV-uninfected patients and more frequent among HIV-infected patients (44.4% vs 91.7%; P p .01): 1 patient died of sepsis, and 1 patient died of multiorgan failure associated with cytomegalovirus pneumonia р2 months after transplantation. The grading of the infectious complications ranged from 2 to 4, with comparable frequency of severe events (grade, 3-4) in the 2 groups (HIV-infected vs HIV-uninfected patients, 77% vs. 75%; P p .92). HIV-infected patients with infective episodes had a significant lower CD4 + T cell count during the third 
DISCUSSION
One of the main concerns with ASCT in HIV-infected patients is the additional immune depletion caused by the transplantation treatment. This could amplify the preexisting immune deficit due to the underlying HIV infection and, thus, undermine control over viral replication ensured by HAART. To date, studies of ASCT in HIV-infected patients have clarified the issues concerning feasibility and effectiveness, but the immunological status and/or the viral dynamics have been analyzed in detail only in few articles [18, 26, 27] , and the data comparing the dynamics of immunological recovery between HIV-infected and HIV-uninfected individuals are scanty.
Our study compared the immunological baseline characteristics in 2 groups of HIV-infected and HIV-uninfected patients with relapsed or refractory lymphoma who began comparable ASCT protocols at our institute. Our data confirmed that frontline chemotherapy produced immunodepression in the general population [28] , although immune impairment is qualitatively different from that observed in HIV-infected patients. In fact, HIV-infected patients had higher CD8 + T cell counts and inverted ratios of CD4 + cells to CD8 + cells, compared with HIV-uninfected patients. Surprisingly, we did not find major differences in the CD4 + cell compartment and thymic reservoir. This result might be because the HIV-infected patients in our study demonstrated good control of HIV RNA levels thanks to previous and ongoing antiretroviral regimens, leading to a reduction of cell activation, proliferation, and apoptosis [16, 29] .
When comparing the dynamics of immunological recovery between the 2 populations, some evident differences at the beginning of the therapeutic program disappeared in the long term. We showed that the CD8 + cell subpopulation, together with CD56 + NK cells, recovered very rapidly in both HIVinfected and HIV-uninfected patients, leading, in the latter group, to a reversal of the ratio of CD4 + cells to CD8 + cells up to 2 years after transplantation. This is a known fact [30] [31] [32] , but with respect to the HIV-infected population in this context, it demonstrated that HDC produced a quite different immune incompetence compared with the former conventional chemotherapy, which mainly affected the CD4 + T subset without a significant impact on the ratio of CD4 + cells to CD8 + cells. With regard to CD4 + T lymphocyte recovery, we observed a temporary setback after the first 3 months after reinfusion in HIV-infected patients; this was followed by a constant increase, which was comparable to that observed in HIV-uninfected patients. The naive CD4 + T lymphocyte count recovered similar to the overall CD4 + T cell subset, but with the relevant increase starting at the 12th month after transplantation. It is worth noting that, in the first 3 months after ASCT, infective episodes occurred significantly more frequently in our HIV-infected cohort. We showed that HIV-infected patients with infections in the early post-ASCT period had significant lower CD4 + T cell counts during the third month after reinfusion, compared with HIV-infected patients who do not have infection. Meanwhile, no correlation emerged between infective episodes and HAART interruptions, lymphoma relapses, or rituximab treatment (data not shown). Moreover, it is relevant to emphasize that no differences either in the frequency of infection or in the dynamics of CD4 + T cell improvement were seen after 3 months after ASCT.
The dynamics of B lymphocyte recovery were comparable in the 2 populations reaching normal values within 6 months. Our results and those of others [33] suggest that rituximab might have had an impact on virtual and persistent depletion of the B compartment.
sjTRECs demonstrated similar kinetics in the 2 cohorts, with median values surpassing the baseline values at 12 months after reinfusion; an additional increase was seen at 2 years in both populations. Only baseline sjTRECs levels were strongly associated with CD4 + cell count and newly generated T cell count at month 12 after ASCT. Overall, the present data indicate, for the first time, that HIV-infected subjects have an efficient thymusdependent pathway of T cell reconstitution after ASCT as well as in HIV-uninfected individuals. As expected [34, 35] , the number of reinfused CD34 + cells per kilogram did correlate with the recovery in B cell, NK cell, and sjTREC counts at month 12 after reinfusion. We confirm that the increase in lymphocyte count, early after engraftment, is mediated by the rapid expansion of preexisting mature cells, whereas the recovery of naive cells starts later because of de novo thymic output [34] [35] [36] [37] .
Therefore, the data on immune reconstitution appeared to be encouraging. Just as reassuring were the data regarding viral control. Altogether, earlier [22] and present evidence suggest that HAART is capable of maintaining viral control even if immune depletion reaches its nadir; reinfusion of HIV-infected autologous cells does not amplify the peripheral HIV reservoir; only the total magnitude of peripheral preexisting HIV reservoir, probably established in the earliest stage of infection, might predict clinical outcome.
In conclusion, the present study demonstrates that HDC and ASCT in HIV-infected patients affected by relapsed or refractory lymphoma do not worsen initial immune impairment or enhance viral replication or peripheral HIV reservoir in the long term. However, in agreement with Díez-Martín et al [14] , we found a transient increase in the incidence of early infective episodes in the HIV-infected cohort versus the general population. In our experience, early infections in HIV-infected patients might be associated with a setback in the CD4 + T cell count increase during the first 3 months after reinfusion. On the whole, these observations indicate that HIV-infected subjects require intensive infection prophylaxis and careful monitoring of immune reconstitution in the early posttransplantation period. In the end, we believe that it might be interesting to explore new immune adjuvant approaches (eg, use of interleukin-2 or interleukin-7) to promote an early CD4 + T cell expansion in the first interval after ASCT, to improve the clinical outcome of HIV-infected patients undergoing autologous transplantation.
